Table 3.
Univariate and multivariate Cox regression analysis identifying PC-LNM as an independent prognostic factor across multiple cancer types.
| Univariate Cox regression analysis | Multivariate Cox regression analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| TCGA cohort (OS) | ||||||
| PC-LNM | 2.7 | 2.03–3.59 | <0.001 | 1.68 | 1.24–2.26 | 0.001 |
| Sex | 1.07 | 0.93–1.24 | 0.356 | / | / | / |
| Age | 1.01 | 1.00–1.02 | 0.0006 | 1.01 | 1.01–1.02 | <0.001 |
| Stage | 1.66 | 1.55–1.79 | <0.001 | 1.64 | 1.51–1.77 | <0.001 |
| CPTAC cohort (OS) | ||||||
| PC-LNM | 74.14 | 7.96–690.25 | <0.001 | 29.80 | 1.14–780.87 | 0.042 |
| Sex | 0.42 | 0.19–0.92 | 0.030 | 0.56 | 0.25–1.28 | 0.170 |
| Age | 1.03 | 0.98–1.09 | 0.230 | / | / | / |
| Stage | 2.32 | 1.41–3.81 | 0.001 | 2.49 | 1.47–4.23 | 0.001 |
PC-LNM pan-cancer lymph node metastasis, HR hazard ratio, CI confidence interval, TCGA The Cancer Genome Atlas, CPTAC Clinical Proteomic Tumour Analysis Consortium, OS overall survival.